CAMBRIDGE, Mass.--(BUSINESS WIRE)--Omega Therapeutics™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the completion of an $85 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results